There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cocrystal Pharma (COCP – Research Report), IGM Biosciences (IGMS – Research Report) and Cidara Therapeutics (CDTX – Research Report) with bullish sentiments.
Cocrystal Pharma (COCP)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cocrystal Pharma, with a price target of $42.00. The company’s shares closed last Friday at $2.39, close to its 52-week low of $2.05.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of
Cocrystal Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $23.50.
See today’s best-performing stocks on TipRanks >>
IGM Biosciences (IGMS)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on IGM Biosciences today and set a price target of $45.00. The company’s shares closed last Friday at $16.50, close to its 52-week low of $12.67.
According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IGM Biosciences with a $35.14 average price target, implying a 102.5% upside from current levels. In a report issued on November 4, Stifel Nicolaus also maintained a Buy rating on the stock with a $50.00 price target.
Cidara Therapeutics (CDTX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics today and set a price target of $6.00. The company’s shares closed last Friday at $0.56, close to its 52-week low of $0.40.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $5.00, implying a 763.7% upside from current levels. In a report issued on November 4, Needham also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COCP:
- MacroGenics (MGNX) Gets a Buy from H.C. Wainwright
- H.C. Wainwright Sticks to Its Buy Rating for Relay Therapeutics (RLAY)
- H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB)
- H.C. Wainwright Sticks to Its Buy Rating for Aurinia Pharmaceuticals (AUPH)
- H.C. Wainwright Keeps Their Buy Rating on Selecta Biosciences (SELB)
